Abstract
In double-blind trials lasting 6 weeks, FDA-approved lurasidone, whether combined with lithium or valproate or as monotherapy, has been effective for treating acute bipolar depression. A manufacturer-supported, open-label, uncontrolled study extends the earlier research by 6 months. The 817 adult outpatient participants (mean age, 43) had bipolar I disorder and major depression but no psychosis (women, 52%; white, 66%). …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
